Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China
Autor: | Dan ying Qiu, Wen xin Li, Jing jing Cheng, Fei hang Ge, Lian peng Wu, Zhen Wang, Dong Chen, Wei Zhang, Wei ling Xiang, Bingyu Chen |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male 0301 basic medicine China Convalescent plasma Coronavirus disease 2019 (COVID-19) Antibodies Viral General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Correspondence Humans Medicine General Pharmacology Toxicology and Pharmaceutics COVID-19 Serotherapy Aged Antibody titer Clinical characteristics General Veterinary business.industry Immunization Passive COVID-19 General Medicine Middle Aged Antibodies Neutralizing 030104 developmental biology Immunoglobulin M Immunoglobulin G 030220 oncology & carcinogenesis Immunology Female business |
Zdroj: | Journal of Zhejiang University. Science. B |
ISSN: | 1862-1783 1673-1581 |
DOI: | 10.1631/jzus.b2000593 |
Popis: | Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first affected humans in China on December 31, 2019 (Shi et al., 2020). Coronaviruses generally cause mild, self-limiting upper respiratory tract infections in humans, such as the common cold, pneumonia, and gastroenteritis (To et al., 2013; Berry et al., 2015; Chan et al., 2015). According to the Report of the World Health Organization (WHO)-China Joint Mission on COVID-19 (WHO, 2020), the case fatality rate of COVID-19 increases with age, while the rate among males is higher than that among females (4.7% and 2.8%, respectively). Since an effective vaccine and specific anti-viral drugs are still under development, passive immunization using the convalescent plasma (CP) of recovered COVID-19 donors may offer a suitable therapeutic strategy for severely ill patients in the meantime. So far, several studies have shown therapeutic efficacy of CP transfusion in treating COVID-19 cases. A pilot study first reported that transfusion of CP with neutralizing antibody titers above 1:640 was well tolerated and could potentially improve clinical outcomes through neutralizing viremia in severe COVID-19 cases (Chen et al., 2020). Immunoglobulin G (IgG) and IgM are the most abundant and important antibodies in protecting the human body from viral attack (Arabi et al., 2015; Marano et al., 2016). Our study aimed to understand the aspects of plasma antibody titer levels in convalescent patients, as well as assessing the clinical characteristics of normal, severely ill, and critically ill patients, and thus provide a basis for guiding CP therapy. We also hoped to find indicators which could serve as a reference in predicting the progression of the disease. |
Databáze: | OpenAIRE |
Externí odkaz: |